Results 101 to 110 of about 1,741,500 (304)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION

HemaSphere, 2023
Madlen Jentzsch, Lara Bischof, Jule Ussmann, Dominic Brauer, Donata Backhaus, Tung Pham Thanh, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind   +9 more
doaj   +1 more source

Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomes

npj Digital Medicine
We developed a novel, explainable artificial intelligence (AI)-driven prognostic model using a contemporary single-centre cohort of 668 patients undergoing haploidentical hematopoietic cell transplantation (HCT) with post-transplantation cyclophosphamide
Rohtesh S. Mehta, Yosra M. Aljawai, Partow Kebriaei, Kai Cao, Jun Zou, Yudith Carmazzi, Gabriela Rondon, Betul Oran, Uday Popat, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall   +11 more
doaj   +1 more source

Developing Cellular Therapies for Stroke [PDF]

Stroke, 2015
Cell therapies refer to the use of cells or cellular material that exert a treatment effect in animal models of disease. During the past 15 years, a range of different types of cell therapies has emerged as potential new treatments that are under development for stroke and other neurological disorders. The past quarter century has witnessed the success
openaire   +2 more sources

Deep Sequencing of FLT3‐ITD Enables Response Evaluation and Post‐Treatment Monitoring in Childhood AML: An Exploratory Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background An internal tandem duplication in the gene encoding Fms‐like tyrosine kinase 3 (FLT3‐ITD) is associated with high relapse risk and poor prognosis in acute myeloid leukemia (AML) and plays a crucial role in treatment decisions. Measurable residual disease (MRD) analysis of FLT3‐ITD during and after treatment has shown prognostic ...
Sofie Johansson Alm, Bea Tornberg, Erik Delsing Malmberg, Henrik Hasle, Kristian Løvvik Juul‐Dam, Lars Palmqvist, Borhan R. Saeed, Giti Shah Barkhordar, Anastasia Soboli, Anna Staffas, Jonas Abrahamsson, Linda Fogelstrand   +11 more
wiley   +1 more source

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population

Haematologica, 2020
Madlen Jentzsch, Marius Bill, Juliane Grimm, Julia Schulz, Luba Schuhmann, Dominic Brauer, Karoline Goldmann, Franziska Wilke, Georg-Nikolaus Franke, Gerhard Behre, Wolfram Pönisch, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind   +14 more
doaj   +1 more source

Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo

Molecular Therapy: Nucleic Acids, 2013
Tumor antigen–encoding mRNA for dendritic cell (DC)-based vaccination has gained increasing popularity in recent years. Within this context, two main strategies have entered the clinical trial stage: the use of mRNA for ex vivo antigen loading of DCs and
Daphné Benteyn, Sébastien Anguille, Sandra Van Lint, Carlo Heirman, An MT Van Nuffel, Jurgen Corthals, Sebastian Ochsenreither, Wim Waelput, Katrien Van Beneden, Karine Breckpot, Viggo Van Tendeloo, Kris Thielemans, Aude Bonehill   +12 more
doaj   +1 more source

Retardation of atherosclerosis in immunocompetent apolipoprotein (apo) E-deficient mice followingliver-directed administration of a [E1-, E3-,polymerase-] adenovirus vector containing the elongation factor-1a promoter driving expression of human apoE cDNA [PDF]

, 2005
Although gene transfer of human apolipoprotein E (apoE), a 34-kDa circulating glycoprotein, to the liver of apoEdeficient(apoE-/-) mice using recombinant adenoviral vectors (rAd) is antiatherogenic, its full therapeutic potentialhas yet to be realized ...
Amalfitano, A, Dickson, G, Graham, IR, Harris, JD, Owen, JS, Schepelmann, S, Stannard, AK   +6 more
core  

Fetal Brain Tumor Harboring a Unique ROCK1::BRAF Fusion

Pediatric Blood &Cancer, EarlyView.
Marllon Cindra Sant'Ana, Mariana Maschietto, Daniela Paz Leal, Ricardo de Santos de Oliveira, Mayara Ferreira Euzébio, Antonio Carlos dos Santos, Luciano Neder, Carlos Alberto Scrideli, Elvis Terci Valera   +8 more
wiley   +1 more source

Claudin‐6 Protein Expression in Atypical Teratoid/Rhabdoid Tumors Is Strongly Enriched in the Molecular Subgroup AT/RT‐TYR

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke, Christian Thomas, Michael C. Frühwald, Pascal D. Johann, Martin Hasselblatt   +4 more
wiley   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source